NUF2 and esophageal squamous cell carcinoma: These results suggest that a high CTL response for CDCA1 critically affects survival efficacy, although differences in study design, such as the control group and number of administered peptides between the phase 2 ESCC study [10] and current phase 3 study, need to be considered.